RSK2 as a key regulator in human skin cancer

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2529-2537

  Cho, Yong Yeon ^a   Lee, Mee Hyun ^b   Lee, Cheol Jung ^a   Yao, Ke ^b   Lee, Hye Suk ^a   Bode, Ann M ^b   Dong, Zigang ^b  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN P90; REGULATOR PROTEIN; RIBOSOMAL S6 KINASE 2; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; KNOCKOUT GENE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; SKIN CANCER; SKIN CARCINOGENESIS; TISSUE MICROARRAY; ULTRAVIOLET B RADIATION;

CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; ULTRAVIOLET RAYS;

EID: 84870327362     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs271     Document Type: Article

References (37)

1. Sebolt-Leopold, J.S. (2000) Development of anticancer drugs targeting the MAP kinase pathway. Oncogene, 19, 6594-6599.
2. Roux, P.P. et al. (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev., 68, 320-344.
3. Jones, S.W. et al. (1988) A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc. Natl. Acad. Sci. U.S.A., 85, 3377-3381.
4. Frödin, M. et al. (2000) A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J., 19, 2924-2934.
5. Frödin, M. et al. (1999) Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol., 151, 65-77.
6. Nebreda, A.R. et al. (1999) Perspectives: signal transduction. Cell survival demands some Rsk. Science, 286, 1309-1310.
7. Cho, Y.Y. et al. (2009) A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res., 69, 4398-4406.
8. Xing, J. et al. (1996) Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science, 273, 959-963.
9. Sassone-Corsi, P. et al. (1999) Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science, 285, 886-891.
10. Blenis, J. (1993) Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. U.S.A., 90, 5889-5892.
11. Davis, R.J. (1995) Transcriptional regulation by MAP kinases. Mol. Reprod. Dev., 42, 459-467.
12. Ward, G.E. et al. (1990) Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C. Cell, 61, 561-577.
13. Cho, Y.Y. et al. (2007) Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res., 67, 8104-8112.
14. Yang, X. et al. (2004) ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: implication for Coffin-Lowry Syndrome. Cell, 117, 387-398.
15. Cho, Y.Y. et al. (2005) The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. Cancer Res., 65, 3596-3603.
16. Cho, Y.Y. et al. (2007) RSK2 mediates muscle cell differentiation through regulation of NFAT3. J. Biol. Chem., 282, 8380-8392.
17. Liu, K. et al. (2011) Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation. J. Biol. Chem., 286, 2057-2066.
18. Pearson, G. et al. (2001) ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J. Biol. Chem., 276, 7927-7931.
19. Schaeffer, H.J. et al. (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol., 19, 2435-2444.
20. Sebolt-Leopold, J.S. et al. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer, 4, 937-947.
21. Bowden, G.T. (2004) Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat. Rev. Cancer, 4, 23-35.
22. Kwa, R.E. et al. (1992) Biology of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol., 26, 1-26.
23. Wan, Y.S. et al. (2001) Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int. J. Oncol., 18, 461-466.
24. Chen, W. et al. (2001) Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene, 20, 3921-3926.
25. Kabuyama, Y. et al. (1998) Wavelength specific activation of PI 3-kinase by UVB irradiation. FEBS Lett., 441, 297-301.
26. Bode, A.M. et al. (2003) Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci. STKE, 2003, RE2.
27. Colburn, N.H. et al. (1981) Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc. Natl. Acad. Sci. U.S.A., 78, 6912-6916.
28. She, Q.B. et al. (2002) Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J. Biol. Chem., 277, 24039-24048.
29. Bonni, A. et al. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science, 286, 1358-1362.
30. Dickson, M.A. et al. (2000) Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol., 20, 1436-1447.
31. Rubin, A.L. et al. (1989) Coordination of keratinocyte programming in human SCC-13 squamous carcinoma and normal epidermal cells. J. Cell. Physiol., 138, 208-214.
32. Mizuno, H. et al. (2006) Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes. Mol. Carcinog., 45, 1-9.
33. Peng, C. et al. (2011) Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J. Biol. Chem., 286, 6946-6954.
34. El-Abaseri, T.B. et al. (2005) Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res., 65, 3958-3965.
35. El-Abaseri, T.B. et al. (2006) Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis, 27, 225-231.
36. David, J.P. et al. (2005) Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J. Clin. Invest., 115, 664-672.
37. Sunters, A. et al. (1998) Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation. Dev. Genet., 22, 386-397.